Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Page Path

Erratum

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]

Seogsong Jeong1,2, Yun Hwan Oh3, Joseph C Ahn4, Seulggie Choi5, Sun Jae Park2, Hye Jun Kim2, Gyeongsil Lee6, Joung Sik Son7, Heejoon Jang8, Dong Hyeon Lee8, Meng Sha9, Lei Chen10,11, Won Kim8,12orcid, Sang Min Park2,6orcid
Clinical and Molecular Hepatology 2025;31(3):1105-1106.
Published online: July 1, 2025

1Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea

2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

3Department of Family Medicine, College of Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea

4Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

5Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

6Department of Family Medicine, Life Clinic, Seoul, Korea

7Department of Internal Medicine, Hanyang University Hospital, Seoul, Korea

8Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea

9Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

10The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China

11National Center for Liver Cancer, Shanghai, China

12Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Corresponding author : Sang Min Park Department of Family Medicine and Biomedical Sciences, College of Medicine, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-3331, Fax: +82-2-766-3276, E-mail: smpark.snuh@gmail.com
Won Kim Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Korea Tel: +82-2-870-2233, Fax: +82-2-831-2826, E-mail: drwon1@snu.ac.kr

Copyright © 2025 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 7,581 Views
  • 26 Download
prev

Full Article

Download PDF Download PDF
This corrects the article "Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study" on page 487.
In the Methods section of the article, the numerical value defining the fatty liver index cutoff was inadvertently misstated. Specifically, the cutoff was written as “≥60” when it should have been “≥30,” as used correctly in all analyses.
We would like to clarify that this error was typographical in nature and does not affect the results, interpretations, or conclusions of the study.
Before correction
Classification of change in MASLD status
The FLI efficiently identifies NAFLD in European and Asian populations, and previous studies have also adopted FLI in the operational definition of steatotic liver disease status [22-25]. MASLD was defined as steatotic liver disease (FLI ≥60) [26] and the presence of at least one of the following cardiometabolic risk factors: body mass index (BMI) ≥23 kg/m2 or waist circumference ≥90 cm (for men) and ≥85 cm (for women) [27], fasting serum glucose ≥100 mg/dL or a history of antidiabetic drug prescription or type 2 diabetes, blood pressure ≥130/85 mm Hg or a history of antihypertensive drug prescription, triglycerides ≥150 mg/dL or a history of lipid-lowering drug prescription, and high-density lipoprotein cholesterol ≤40 mg/dL (for men) and ≤50 mg/dL (for women) [20].
After correction
Classification of change in MASLD status
The FLI efficiently identifies NAFLD in European and Asian populations, and previous studies have also adopted FLI in the operational definition of steatotic liver disease status [22-25]. MASLD was defined as steatotic liver disease (FLI ≥30) [26] and the presence of at least one of the following cardiometabolic risk factors: body mass index (BMI) ≥23 kg/m2 or waist circumference ≥90 cm (for men) and ≥85 cm (for women) [27], fasting serum glucose ≥100 mg/dL or a history of antidiabetic drug prescription or type 2 diabetes, blood pressure ≥130/85 mm Hg or a history of antihypertensive drug prescription, triglycerides ≥150 mg/dL or a history of lipid-lowering drug prescription, and high-density lipoprotein cholesterol ≤40 mg/dL (for men) and ≤50 mg/dL (for women) [20].

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
Clin Mol Hepatol. 2025;31(3):1105-1106.   Published online July 1, 2025
DOI: https://doi.org/10.3350/cmh.2024.0145e
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
Format:
Include:
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
Clin Mol Hepatol. 2025;31(3):1105-1106.   Published online July 1, 2025
DOI: https://doi.org/10.3350/cmh.2024.0145e
Close

Related articles

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]
CMH : Clinical and Molecular Hepatology
Twitter

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS

© The Korean Association for the Study of the Liver.